Nicole LaBrosse serves as the Senior Vice President and Chief Financial Officer at Halozyme Therapeutics Inc., a biopharmaceutical company focused on developing and commercializing novel oncology therapies. In her role, LaBrosse is responsible for overseeing the company's financial operations, including financial planning and analysis, accounting, investor relations, and treasury. Her strategic financial leadership has been instrumental in guiding Halozyme through significant growth and development phases, ensuring the company's fiscal health and supporting its mission to deliver innovative treatments to patients. Prior to joining Halozyme, LaBrosse held several key financial leadership positions in the biopharmaceutical industry. She previously served as the Chief Financial Officer at Aimmune Therapeutics, where she played a pivotal role in the company's successful IPO and subsequent growth. Before Aimmune, she was the Vice President of Finance at InterMune, where she contributed to the company's financial strategy and operations until its acquisition by Roche. LaBrosse's extensive experience in financial management within the life sciences sector has equipped her with the expertise needed to navigate the complex financial landscapes of biopharmaceutical companies. LaBrosse's achievements in her field are marked by her ability to drive financial performance and strategic growth. At Halozyme, she has been key in securing funding and managing the company's resources to support ongoing research and development efforts. Her leadership has not only strengthened Halozyme's financial position but also enhanced its reputation as a forward-thinking and financially robust organization in the competitive biopharmaceutical industry.